TARCEVA is a kinase inhibitor indicated for • Maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. • Treatment of locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. • First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of TARCEVA (erlotinib) tablets brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the TARCEVA (erlotinib) tablets medicine cost price in India.
The order for TARCEVA (erlotinib) tablets will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Erlotinib, sold under the brand name Tarceva among others, is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. Specifically it is used for NSCLC with either an EGFR exon 19 deletion (del19) or exon 21 (L858R) substitution mutation which has spread to other parts of the body.
TARCEVA® (erlotinib) tablets, oral Initial U.S. Approval: 2004
Generic Name: erlotinib
Tablets: 25 mg, 100 mg and 150 mg.
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand TARCEVA (erlotinib) tablets on prescription and Import License in Patient's Name only.
For overseas patients, TARCEVA (erlotinib) tablets can be made available in Send your enquiry to find TARCEVA (erlotinib) tablets in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For TARCEVA (erlotinib) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
Breckenridge Announces Final Approval of ANDA for Erlotinib Hydrochloride Tablets (generic for Tarceva®) For More Details
Armas Pharmaceuticals Announces Launch of Oncology Generic Erlotinib For More Details